Alpine Immune Sciences (ALPN)

Company Profile

founded in 2015 by a team responsible for the fda's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, alpine immune sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. traded on nasdaq under ticker alpn.

Company profile

Ticker

ALPN

Exchange

NASDAQ

Website

alpineimmunesciences.com

CEO

Mitchell Gold

Incorporated

Delaware

Location

Washington

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies • Celgene ...

Former names

N30 Pharmaceuticals, Inc., Nivalis Therapeutics, Inc.

SEC CIK

0001626199

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

AIS Operating Co., Inc. • Alpine Immune Sciences Australia PTY LTD ...

ALPN stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

14 Nov 23

Alpine Immune Sciences Reports Third Quarter 2023 Financial Results

14 Nov 23

8-K

Entry into a Material Definitive Agreement

7 Nov 23

424B5

Prospectus supplement for primary offering

7 Nov 23

FWP

Free writing prospectus

6 Nov 23

424B5

Prospectus supplement for primary offering

6 Nov 23

8-K

Results of Operations and Financial Condition

Notice of effectiveness

17 Aug 23

POS AM

Prospectus update (post-effective amendment)

14 Aug 23

Transcripts

View all

ALPN

Earnings call transcript

2022 Q4

23 Mar 23

ALPN

Earnings call transcript

2022 Q3

14 Nov 22

ALPN

Earnings call transcript

2021 Q2

11 Aug 21

ALPN

Earnings call transcript

2020 Q4

19 Mar 21

ALPN

Earnings call transcript

2020 Q3

12 Nov 20

ALPN

Earnings call transcript

2020 Q2

11 Aug 20

ALPN

Earnings call transcript

2019 Q4

30 Mar 20

ALPN

Earnings call transcript

2019 Q3

13 Nov 19

Latest ownership filings

View all

James Paul Rickey

1 Dec 23

SC 13D/A

Frazier Life Sciences VIII, L.P.

22 Nov 23

SC 13D/A

Decheng Capital China Life Sciences USD Fund III, L.P.

14 Nov 23

Xiangmin Cui

14 Nov 23

Change in insider ownership

14 Nov 23

SC 13D/A

Alpine ImmunoSciences, L.P.

Notice of proposed sale of securities

6 Nov 23

SC 13G

Cormorant Asset Management, LP

23 Oct 23

Financial summary

Financial statements Chart ALPN financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	19.24 mm	19.24 mm	19.24 mm	19.24 mm	19.24 mm	19.24 mm
Cash burn (monthly)	5.03 mm	8.97 mm	4.85 mm	5.51 mm	5.27 mm	6.40 mm
Cash used (since last report)	10.58 mm	18.87 mm	10.20 mm	11.60 mm	11.08 mm	13.47 mm
Cash remaining	8.65 mm	365.50 k	9.03 mm	7.64 mm	8.16 mm	5.77 mm
Runway (months of cash)	1.7	0.0	1.9	1.4	1.5	0.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2023

ALPN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	93	81	+14.8%
Opened positions	17	18	-5.6%
Closed positions	5	2	+150.0%
Increased positions	34	34	–
Reduced positions	21	12	+75.0%

13F shares	Current	Prev Q	Change
Total value	508.98 bn	363.47 bn	+40.0%
Total shares	60.58 mm	51.65 mm	+17.3%
Total puts	0.00	0.00
Total calls	1.70 k	2.30 k	-26.1%
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Decheng Capital Management III	6.71 mm	$76.81 bn	NEW
Decheng Capital China Life Sciences USD Fund III	6.58 mm	$45.35 mm	0.0%
Ra Capital Management	4.69 mm	$53.71 bn	0.0%
Orbimed Advisors	4.08 mm	$46.73 bn	0.0%
Great Point Partners	3.08 mm	$35.25 bn	-8.5%
Frazier Life Sciences Management	2.99 mm	$34.19 bn	0.0%
Alpine ImmunoSciences	2.68 mm	$18.43 mm	0.0%
Paradigm Biocapital Advisors	2.42 mm	$27.73 bn	-0.1%
Omega Fund VI	2.42 mm	$0.00	0.0%
Lynx1 Capital Management	2.40 mm	$27.53 bn	-10.0%

Largest transactions	Shares	Bought/sold	Change
Decheng Capital Management III	6.71 mm	+6.71 mm	NEW
Cormorant Asset Management	1.90 mm	+1.90 mm	NEW
Omega Fund Management	153.70 k	-1.88 mm	-92.4%
T. Rowe Price	1.40 mm	+1.37 mm	+6323.4%
Woodline Partners	1.04 mm	+801.21 k	+337.3%
Avidity Partners Management	657.28 k	-401.22 k	-37.9%
Ghost Tree Capital	664.13 k	+316.70 k	+91.2%
Great Point Partners	3.08 mm	-285.06 k	-8.5%
Lynx1 Capital Management	2.40 mm	-265.86 k	-10.0%
TCG Crossover Management	0.00	-253.07 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALPN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Nov 23	Rickey James Paul	Common Stock	Sell	Dispose S	No	Yes	16	700	11.20 k	0
30 Nov 23	Rickey James Paul	Common Stock	Option exercise	Acquire M	No	Yes	3.23	700	2.26 k	700
30 Nov 23	Rickey James Paul	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	3.23	700	2.26 k	90,311
9 Nov 23	Xiangmin Cui	Common Stock	Buy	Acquire P	Yes	No	12.5	375,000	4.69 mm	1,735,544
9 Nov 23	Decheng Capital Global Healthcare Fund	Common Stock	Buy	Acquire P	No	No	12.5	375,000	4.69 mm	1,735,544
6 Nov 23	Rickey James Paul	Common Stock	Sell	Dispose S	No	Yes	16.0281	18,003	288.55 k	0
6 Nov 23	Rickey James Paul	Common Stock	Option exercise	Acquire M	No	Yes	3.23	10,989	35.49 k	18,003
6 Nov 23	Rickey James Paul	Stock Option Common Stock	Option exercise	Dispose M	No	Yes	3.23	10,989	35.49 k	91,011